Biotechnology
Scientists have developed and assessed the performance of IgG and IgM enzyme-linked immunosorbent assays (ELISAs) using a West Nile virus (WNV) recombinant antigen for the detection of WNV- and other flavivirus-specific antibodies. The assays were developed by Focus Technologies and evaluated using serum panels from normal and diseased individuals. The
Biotechnology
Scientists at the Jagiellonian University have discovered that Mycobacterium vaccae modulates monocyte-tumor cell interactions, with significant implications for cancer immunotherapy. The study, published in the journal Cancer Immunology Immunotherapy, reveals that Mycobacterium vaccae can prevent or reverse deactivation of monocytes, which occurs when they come into contact with tumor cells.
Communicable diseases
A recent study from the United States has shed light on the effectiveness of different immunosuppressive regimens in preventing hepatitis C recurrence after liver transplants. The research, conducted by P. Martin and colleagues from the Liver Transplantation Program at Cedars Sinai Medical Center, aimed to investigate whether the choice of
Communicable diseases
Researchers from the United States have successfully demonstrated the effectiveness of porcine adenoviral vectors in gene delivery, addressing the limitations of human adenoviral vectors due to preexisting immunity. Porcine adenovirus serotype 3 (PAD)-based vectors were found to evade preexisting humoral immunity to adenoviruses and efficiently infect both human and
Biotechnology
Researchers from the United States have found that parenteral vaccine adjuvants can promote systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. The study aimed to evaluate the ability of adjuvants to augment peptide-specific immune responses. The findings suggest that parenteral vaccine administration in combination with the appropriate
Biotechnology
A DNA prime/vaccinia virus boost immunization regime has shown promise in eliciting an efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates. This study, conducted by Spanish researchers, analyzed the antigen-specific immune responses triggered in mice by different combinations of vaccine vehicles expressing
Communicable diseases
Women infected with HIV may transfer lower levels of protective antibodies to their babies during pregnancy, making them more vulnerable to infections, according to a study published in 2004. The research, conducted by Shahana Choudhury and her team at Meharry Medical College, found that mothers with the lowest CD4 positive
Communicable diseases
Researchers from England have published a study in the journal Vaccine, demonstrating the effectiveness of whole cell and acellular pertussis vaccines in providing mucosal immunization of murine neonates. The study found that neonatal mice tolerated mucosal vaccination well and showed a significant cellular infiltrate in the lungs compared to PBS
Communicable diseases
De novo immune hepatitis, a type of autoimmune hepatitis, has been linked to a genetic mismatch in liver transplant patients. Specifically, a study from Spain found that a mismatch in the glutathione S-transferase T1 (GSTT1) gene between donor and recipient increases the risk of this condition. Researchers analyzed a cohort
Communicable diseases
A team of scientists from Innsbruck Medical University has made a groundbreaking discovery in the fight against fungal infections. By genetically blocking the iron metabolism of Aspergillus fumigatus mold, they have found a promising approach to developing new therapies against deadly fungal infections. This breakthrough has significant implications for patients
Biotechnology
Research from the University of Hohenheim in Germany has found that DNA vaccination can protect mice against lethal challenge with Bacillus anthracis STI spores. The study published in the International Journal of Medical Microbiology used three different plasmid vectors to encode the protective antigen (PA) of B. anthracis, which is
Biotechnology
Scientists in Sweden conducted a phase I trial to evaluate the safety, feasibility, and biological efficacy of a DNA vaccine expressing prostate-specific antigen (PSA) in patients with hormone-refractory prostate cancer. The study's objective was to assess whether DNA vaccination could induce an immune response against PSA in patients
